Skip to main content
Not investment advice. Educational platform. See Disclaimer.
NASDAQ: ANAB

AnaptysBio, Inc.

Healthcare | Biotechnology

No licensed closing price on file for ANAB. This page shows the company’s SEC filings and filed figures, without a price or any ratio that depends on one.

EPS (TTM)$-1.02

AnaptysBio, Inc. (NASDAQ: ANAB) is a biotechnology company. Figures from SEC EDGAR; updated 2026-10-20 09:34 UTC.

What AnaptysBio, Inc. does

The company is a clinical-stage biotechnology firm developing immunology therapeutics for autoimmune and inflammatory diseases. Its main pipeline includes rosnilimab, a selective T cell depleter that completed a Phase 2b trial for rheumatoid arthritis, along with ANB033 in Phase 1b for celiac disease and eosinophilic esophagitis, and ANB101 in Phase 1a. The company also discovered and out-licensed therapeutic antibodies to other firms, generating current revenue through milestone payments and royalties from collaborations with GSK and Vanda Pharmaceuticals.

Summarized from AnaptysBio, Inc.’s SEC filings · AI-generated analysis. Not investment advice. May contain errors. · Read the filing ↗

Pre-revenue, development-stage company: standard profitability ratios (P/E, EV/EBITDA, ROE) do not apply yet because there are no earnings. Watch cash, cash runway, net loss, R&D spend and share dilution instead.

Key facts

Valuation
EPS (TTM)$-1.02

Revenue, margins & earnings

FY2021: net loss $58M on revenue $63M$63MFY2021FY2022: net loss $129M on revenue $10M$10MFY2022FY2023: net loss $164M on revenue $17M$17MFY2023FY2024: net loss $145M on revenue $91M$91MFY2024FY2025: net loss $13M on revenue $235M$235MFY2025
  • Net income
  • Taxes & interest
  • Operating costs
  • Net loss year
Annual revenue; bands show net, operating margins · Open in Platform →

SEC Filings

SEC EDGAR ↗
Recent Insider Activity (last 90 days)
Source: SEC EDGAR · Filed 2026-10-02
  • 2026-10-02DirectorCommon StockOption exercise-5,000—
  • 2026-10-02DirectorOption exercise5,000$90.2K
  • 2026-10-02DirectorSale-5,000$249.4K
Sign in to see all transactions →
Recent 8-K Events (parsed from SEC filings)All events →
Source: SEC EDGAR 8-K filings · Interpretation: Oxford Ledge parser · Confidence-filtered ≥ 0.50

Company news

View all →

Questions this page answers

What does AnaptysBio, Inc. do?

The company is a clinical-stage biotechnology firm developing immunology therapeutics for autoimmune and inflammatory diseases.

When did ANAB last file with the SEC?

AnaptysBio, Inc.'s most recent SEC filing on record is a DEF 14A filed 2026-06-29. All filings link to their SEC EDGAR originals above.

Where does this data come from?

SEC EDGAR filings, with the company profile (sector, industry, exchange) from public data providers, fetched 2026-10-20 09:34 UTC. This page is also available as JSON at /api/data?ticker=ANAB and is emitted with FAQPage structured data for machine reading.

For you

Charts, 10-year financials, peer comparison, screening and portfolio tracking for ANAB and 5,000+ tickers.

Create a free account — keep ANAB
For your agent
GET /api/data?ticker=ANAB

This page as JSON via rel="alternate" · REST API docs · MCP server (60 tools) · llms.txt